Tenascin‐C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression
Abstract Immune checkpoint therapy, where CD8 tumor infiltrating T lymphocytes (TIL) are reactivated, is a promising anti‐cancer treatment approach, yet with low response rates. The extracellular matrix, in particular tenascin‐C, may generate barriers for TIL. To investigate this possibility, we use...
Main Authors: | Devadarssen Murdamoothoo, Zhen Sun, Alev Yilmaz, Gilles Riegel, Chérine Abou‐Faycal, Claire Deligne, Ines Velazquez‐Quesada, William Erne, Marine Nascimento, Matthias Mörgelin, Gérard Cremel, Nicodème Paul, Raphael Carapito, Romain Veber, Hélène Dumortier, Jingping Yuan, Kim S Midwood, Thomas Loustau, Gertraud Orend |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2021-05-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.202013270 |
Similar Items
-
Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies
by: Sayda Dhaouadi, et al.
Published: (2021-03-01) -
Editorial: Tenascins – Key Players in Tissue Homeostasis and Defense
by: Kyoko Imanaka Yoshida, et al.
Published: (2022-01-01) -
Did Tenascin-C Co-Evolve With the General Immune System of Vertebrates?
by: Gertraud Orend, et al.
Published: (2021-04-01) -
Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers
by: Ismaïl Hendaoui, et al.
Published: (2021-02-01) -
Revisiting the Tenascins: Exploitable as Cancer Targets?
by: Richard P. Tucker, et al.
Published: (2022-06-01)